HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Metabolic neuropathy — Clinical Guidelines

Overview

Metabolic neuropathies encompass a range of neurological disorders resulting from inherited metabolic defects, often characterized by the accumulation of toxic metabolites such as phytanic acid, leading to peripheral neuropathy and other systemic manifestations. 1 3

Diagnosis

Elevated phytanic acid levels: Serum phytanic acid concentration typically above 0.2 mg/dL. 1 3

Deficient phytanic acid oxidase activity: Fibroblast enzyme activity below normal range (23 to 87 pmol/mg protein/hr). 3

Increased pipecolic acid levels: Serum pipecolic acid elevated, often 7 to 55 times normal. 3

Abnormal very long chain fatty acids: Elevated C26/C22 ratio (>0.03). 3

Clinical features: Characteristic facial dysmorphism, sensorineural hearing loss, visual impairment, hypotonia, hepatomegaly, and developmental delay. 3

Peripheral nerve biopsy: May show morphological changes indicative of neuropathy. 5

Management

Dietary restriction: Avoidance of foods containing phytanic acid (e.g., ruminant meat, certain dairy products). 1

Supportive care: Management of symptoms including physical therapy for neuropathy, hearing aids, and visual aids. 3

Vitamin supplementation: Address deficiencies identified, such as vitamin K for clotting defects. 3

Monitoring: Regular assessment of metabolic parameters and clinical progression. 3

Special Populations

Pediatrics: Early diagnosis crucial due to severe developmental delay and multisystem involvement. 3

Comorbidities: Consider vitamin K deficiency and associated coagulopathies in management plans. 3

Key Recommendations

Assess serum phytanic acid levels and fibroblast phytanic acid oxidase activity in atypical chronic peripheral neuropathies (Evidence: Moderate 3).

Implement dietary restrictions to avoid phytanic acid intake (Evidence: Expert opinion 1).

Regularly monitor clinical and metabolic parameters in affected individuals (Evidence: Moderate 3).

Provide supportive care tailored to specific symptoms such as hearing loss and visual impairment (Evidence: Expert opinion 3).

References

1 Hirji S, Tsang S, Sharma T, Diaconita V. Inborn Errors of Metabolism: Refsum Disease. Advances in experimental medicine and biology 2025. link 2 Champion A, Griffiths K, Gooley AA, Gonzalez BY, Gritzali M, West CM et al.. Immunochemical, genetic and morphological comparison of fucosylation mutants of Dictyostelium discoideum. Microbiology (Reading, England) 1995. link 3 Budden SS, Kennaway NG, Buist NR, Poulos A, Weleber RG. Dysmorphic syndrome with phytanic acid oxidase deficiency, abnormal very long chain fatty acids, and pipecolic acidemia: studies in four children. The Journal of pediatrics 1986. link80765-x) 4 Sweet JB, Callihan MD, Schaefer EJ, Tarpley TM. Tangier disease with oral abnormalities. International journal of oral surgery 1983. link80006-4) 5 Savettieri G, Camarda R, Galatioto S, Bonavita V. Refsum disease. Clinical and morphological report on a case. Italian journal of neurological sciences 1982. link

Metabolic neuropathy